Surgical Management of Soft Tissue Sarcoma in the Geriatric Population

  • Charlotte E. Ariyan
  • Murray F. Brennan


The management of soft tissue sarcomas in the elderly ­population requires a multidisciplinary approach. These rare tumors have a wide range of growth patterns and metastatic potential, much of which can be discerned by the pathologic subtype. Increasing age alone has repeatedly been demonstrated to have a negative impact on death from this disease. While surgery continues to be the primary treatment for ­sarcomas, radiation and chemotherapy have selective utility. The benefits of an aggressive approach must be weighed against the morbidity of treatment, particularly in the ­geriatric population.


Soft Tissue Sarcoma Familial Adenomatous Polyposis Intensity Modulate Radiation Therapy Negative Margin Malignant Peripheral Nerve Sheath Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, Li FP, Fraumeni JF Jr (2005) Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 23:2272–2279PubMedCrossRefGoogle Scholar
  2. 2.
    Kleinerman RA, Tucker MA, Abramson DH, Seddon JM, Tarone RE, Fraumeni JF Jr (2007) Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 99:24–31PubMedCrossRefGoogle Scholar
  3. 3.
    Brady MS, Gaynor JJ, Brennan MF (1992) Radiation-associated sarcoma of bone and soft tissue. Arch Surg 127:1379–1385PubMedCrossRefGoogle Scholar
  4. 4.
    Cha C, Antonescu CR, Quan ML, Maru S, Brennan MF (2004) Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg 239:903–909, discussion 909–910PubMedCrossRefGoogle Scholar
  5. 5.
    Stewart FW, Treves N (1948) Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer 1:64–81PubMedCrossRefGoogle Scholar
  6. 6.
    Kang H, Enzinger FM, Breslin P, Feil M, Lee Y, Shepard B (1987) Soft tissue sarcoma and military service in Vietnam: a case-control study. J Natl Cancer Inst 79:693–699PubMedGoogle Scholar
  7. 7.
    Gennaro V, Ceppi M, Crosignani P, Montanaro F (2008) Reanalysis of updated mortality among vinyl and polyvinyl chloride workers: confirmation of historical evidence and new findings. BMC Public Health 8:21PubMedCrossRefGoogle Scholar
  8. 8.
    AJCC (2002) AJCC cancer staging manual. Lippincott Raven Publishers, ChicagoGoogle Scholar
  9. 9.
    Kattan MW, Leung DH, Brennan MF (2002) Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 20:791–796PubMedCrossRefGoogle Scholar
  10. 10.
    Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, Casali PG, Gronchi A (2005) Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 103:402–408PubMedCrossRefGoogle Scholar
  11. 11.
    Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D (1987) Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 205:349–359PubMedCrossRefGoogle Scholar
  12. 12.
    Heslin MJ, Lewis JJ, Woodruff JM, Brennan MF (1997) Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol 4:425–431PubMedCrossRefGoogle Scholar
  13. 13.
    Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, DeMoss EV, Seipp C, Sindelar WF, Sugarbaker P, Wesley R (1982) The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 196:305–315PubMedCrossRefGoogle Scholar
  14. 14.
    Williard WC, Hajdu SI, Casper ES, Brennan MF (1992) Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 215:269–275PubMedCrossRefGoogle Scholar
  15. 15.
    Kooby DA, Antonescu CR, Brennan MF, Singer S (2004) Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: importance of histological subtype with treatment recommendations. Ann Surg Oncol 11:78–84PubMedCrossRefGoogle Scholar
  16. 16.
    Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, Brennan MF, Lewis JJ (2000) Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and ­followed at a single institution. Cancer 88:2711–2720PubMedCrossRefGoogle Scholar
  17. 17.
    Merchant NB, Lewis JJ, Woodruff JM, Leung DH, Brennan MF (1999) Extremity and trunk desmoid tumors: a multifactorial ­analysis of outcome. Cancer 86:2045–2052PubMedCrossRefGoogle Scholar
  18. 18.
    Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA, Fletcher CD (1996) Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 20:391–405PubMedCrossRefGoogle Scholar
  19. 19.
    Angervall L, Kindblom LG, Merck C (1977) Myxofibrosarcoma. A study of 30 cases. Acta Pathol Microbiol Scand [A] 85A:127–140Google Scholar
  20. 20.
    Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR (2004) Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol 35:612–621PubMedCrossRefGoogle Scholar
  21. 21.
    Waters B, Panicek DM, Lefkowitz RA, Antonescu CR, Healey JH, Athanasian EA, Brennan MF (2007) Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease. AJR Am J Roentgenol 188:W193–W198PubMedCrossRefGoogle Scholar
  22. 22.
    Stewart FW, Treves N (1981) Classics in oncology: lymphangiosarcoma in postmastectomy lymphedema: a report of six cases in elephantiasis chirurgica. CA Cancer J Clin 31:284–299PubMedCrossRefGoogle Scholar
  23. 23.
    Strobbe LJ, Peterse HL, van Tinteren H, Wijnmaalen A, Rutgers EJ (1998) Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforeseen sequela. Breast Cancer Res Treat 47:101–109PubMedCrossRefGoogle Scholar
  24. 24.
    Naka N, Ohsawa M, Tomita Y, Kanno H, Uchida A, Myoui A, Aozasa K (1996) Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases. J Surg Oncol 61:170–176PubMedCrossRefGoogle Scholar
  25. 25.
    Vauthey JN, Woodruff JM, Brennan MF (1995) Extremity malignant peripheral nerve sheath tumors (neurogenic sarcomas): a 10-year experience. Ann Surg Oncol 2:126–131PubMedCrossRefGoogle Scholar
  26. 26.
    Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF (1996) Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 14:859–868PubMedGoogle Scholar
  27. 27.
    O’Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Kandel R, Goddard K, Sadura A, Pater J, Zee B (2002) Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 359:2235–2241PubMedCrossRefGoogle Scholar
  28. 28.
    Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA (1998) Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16:197–203PubMedGoogle Scholar
  29. 29.
    Baldini EH, Goldberg J, Jenner C, Manola JB, Demetri GD, Fletcher CD, Singer S (1999) Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 17:3252–3259PubMedGoogle Scholar
  30. 30.
    Lin PP, Schupak KD, Boland PJ, Brennan MF, Healey JH (1998) Pathologic femoral fracture after periosteal excision and radiation for the treatment of soft tissue sarcoma. Cancer 82:2356–2365PubMedCrossRefGoogle Scholar
  31. 31.
    Alektiar KM, Hong L, Brennan MF, Della-Biancia C, Singer S (2007) Intensity modulated radiation therapy for primary soft tissue sarcoma of the extremity: preliminary results. Int J Radiat Oncol Biol Phys 68:458–464PubMedCrossRefGoogle Scholar
  32. 32.
    Rosenberg SA, Tepper J, Glatstein E, Costa J, Young R, Baker A, Brennan MF, Demoss EV, Seipp C, Sindelar WF, Sugarbaker P, Wesley R (1983) Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer 52:424–434PubMedCrossRefGoogle Scholar
  33. 33.
    Chang AE, Kinsella T, Glatstein E, Baker AR, Sindelar WF, Lotze MT, Danforth DN Jr, Sugarbaker PH, Lack EE, Steinberg SM et al (1988) Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol 6:1491–1500PubMedGoogle Scholar
  34. 34.
    (1997) Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 350:1647–1654Google Scholar
  35. 35.
    Antman KH, Elias A, Ryan L (1990) Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol 17:68–73PubMedGoogle Scholar
  36. 36.
    Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P (2001) Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19:1238–1247PubMedGoogle Scholar
  37. 37.
    Frustaci S, De Paoli A, Bidoli E, La Mura N, Berretta M, Buonadonna A, Boz G, Gherlinzoni F (2003) Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 65(Suppl 2):80–84PubMedCrossRefGoogle Scholar
  38. 38.
    Grobmyer SR, Maki RG, Demetri GD, Mazumdar M, Riedel E, Brennan MF, Singer S (2004) Neo-adjuvant chemotherapy for ­primary high-grade extremity soft tissue sarcoma. Ann Oncol 15:1667–1672PubMedCrossRefGoogle Scholar
  39. 39.
    Chang HR, Hajdu SI, Collin C, Brennan MF (1989) The prognostic value of histologic subtypes in primary extremity liposarcoma. Cancer 64:1514–1520PubMedCrossRefGoogle Scholar
  40. 40.
    Gebhard S, Coindre JM, Michels JJ, Terrier P, Bertrand G, Trassard M, Taylor S, Chateau MC, Marques B, Picot V, Guillou L (2002) Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 26:601–616PubMedCrossRefGoogle Scholar
  41. 41.
    Antonescu CR, Tschernyavsky SJ, Decuseara R, Leung DH, Woodruff JM, Brennan MF, Bridge JA, Neff JR, Goldblum JR, Ladanyi M (2001) Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 7:3977–3987PubMedGoogle Scholar
  42. 42.
    McCormick D, Mentzel T, Beham A, Fletcher CD (1994) Dedifferentiated liposarcoma. Clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am J Surg Pathol 18:1213–1223PubMedCrossRefGoogle Scholar
  43. 43.
    Henricks WH, Chu YC, Goldblum JR, Weiss SW (1997) Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 21:271–281PubMedCrossRefGoogle Scholar
  44. 44.
    Eilber FC, Eilber FR, Eckardt J, Rosen G, Riedel E, Maki RG, Brennan MF, Singer S (2004) The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 240:686–695, discussion 695–687PubMedGoogle Scholar
  45. 45.
    Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM, Brennan MF (2000) Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 18:2087–2094PubMedGoogle Scholar
  46. 46.
    Eilber FC, Brennan MF, Eilber FR, Eckardt JJ, Grobmyer SR, Riedel E, Forscher C, Maki RG, Singer S (2007) Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 246:105–113PubMedCrossRefGoogle Scholar
  47. 47.
    Lewis JJJ, Leung DD, Woodruff JJM, Brennan MMF (1998) Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 228:355–365PubMedCrossRefGoogle Scholar
  48. 48.
    Singer S, Antonescu CR, Riedel E, Brennan MF (2003) Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 238:358–370, discussion 370–351PubMedGoogle Scholar
  49. 49.
    Hollenbeck ST, Grobmyer SR, Kent KC, Brennan MF (2003) Surgical treatment and outcomes of patients with primary inferior vena cava leiomyosarcoma. J Am Coll Surg 197:575–579PubMedCrossRefGoogle Scholar
  50. 50.
    Fabre-Guillevin E, Coindre JM, Somerhausen Nde S, Bonichon F, Stoeckle E, Bui NB (2006) Retroperitoneal liposarcomas: follow-up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas. Cancer 106:2725–2733PubMedCrossRefGoogle Scholar
  51. 51.
    Karakousis CP, Velez AF, Gerstenbluth R, Driscoll DL (1996) Resectability and survival in retroperitoneal sarcomas. Ann Surg Oncol 3:150–158PubMedCrossRefGoogle Scholar
  52. 52.
    Tepper JE, Suit HD, Wood WC, Proppe KH, Harmon D, McNulty P (1984) Radiation therapy of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys 10:825–830PubMedCrossRefGoogle Scholar
  53. 53.
    Sindelar WF, Kinsella TJ, Chen PW, DeLaney TF, Tepper JE, Rosenberg SA, Glatstein E (1993) Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. Arch Surg 128:402–410PubMedCrossRefGoogle Scholar
  54. 54.
    Pawlik TM, Pisters PW, Mikula L, Feig BW, Hunt KK, Cormier JN, Ballo MT, Catton CN, Jones JJ, O’Sullivan B, Pollock RE, Swallow CJ (2006) Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol 13:508–517PubMedCrossRefGoogle Scholar
  55. 55.
    Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D et al (1991) Identification of FAP locus genes from chromosome 5q21. Science 253:661–665PubMedCrossRefGoogle Scholar
  56. 56.
    Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton SR, Hedge P, Markham A et al (1991) Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251:1366–1370PubMedCrossRefGoogle Scholar
  57. 57.
    Latchford A, Volikos E, Johnson V, Rogers P, Suraweera N, Tomlinson I, Phillips R, Silver A (2007) APC mutations in FAP-associated desmoid tumours are non-random but not ‘just right’. Hum Mol Genet 16:78–82PubMedCrossRefGoogle Scholar
  58. 58.
    Xu W, Kimelman D (2007) Mechanistic insights from structural studies of beta-catenin and its binding partners. J Cell Sci 120:3337–3344PubMedCrossRefGoogle Scholar
  59. 59.
    Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, Warneke CL, Lopez-Terrada D, Pollock RE, Lev D (2008) Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 173:1518–1527PubMedCrossRefGoogle Scholar
  60. 60.
    Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ (1997) Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 151:329–334PubMedGoogle Scholar
  61. 61.
    Shitoh K, Konishi F, Iijima T, Ohdaira T, Sakai K, Kanazawa K, Miyaki M (1999) A novel case of a sporadic desmoid tumour with mutation of the beta catenin gene. J Clin Pathol 52:695–696PubMedCrossRefGoogle Scholar
  62. 62.
    Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, Van Cutsem E, Bapat B, van Roy F, Cassiman JJ, Alman BA (1999) Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 18:6615–6620PubMedCrossRefGoogle Scholar
  63. 63.
    Miyoshi Y, Iwao K, Nawa G, Yoshikawa H, Ochi T, Nakamura Y (1998) Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol Res 10:591–594PubMedGoogle Scholar
  64. 64.
    Anthony T, Rodriguez-Bigas MA, Weber TK, Petrelli NJ (1996) Desmoid tumors. J Am Coll Surg 182:369–377PubMedGoogle Scholar
  65. 65.
    Bruce JM, Bradley EL 3rd, Satchidanand SK (1996) A desmoid tumor of the pancreas. Sporadic intra-abdominal desmoids revisited. Int J Pancreatol 19:197–203PubMedGoogle Scholar
  66. 66.
    Humar A, Chou S, Carpenter B (1993) Fibromatosis in infancy and childhood: the spectrum. J Pediatr Surg 28:1446–1450PubMedCrossRefGoogle Scholar
  67. 67.
    Spear MA, Jennings LC, Mankin HJ, Spiro IJ, Springfield DS, Gebhardt MC, Rosenberg AE, Efird JT, Suit HD (1998) Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys 40:637–645PubMedCrossRefGoogle Scholar
  68. 68.
    Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G (2004) High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 100:612–620PubMedCrossRefGoogle Scholar
  69. 69.
    Latchford AR, Sturt NJ, Neale K, Rogers PA, Phillips RK (2006) A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis. Br J Surg 93:1258–1264PubMedCrossRefGoogle Scholar
  70. 70.
    Dematteo RP, Gold JS, Saran L, Gonen M, Liau KH, Maki RG, Singer S, Besmer P, Brennan MF, Antonescu CR (2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112:608–615PubMedCrossRefGoogle Scholar
  71. 71.
    Raut CP, DeMatteo RP (2008) Prognostic factors for primary GIST: prime time for personalized therapy? Ann Surg Oncol 15:4–6PubMedCrossRefGoogle Scholar
  72. 72.
    Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580PubMedCrossRefGoogle Scholar
  73. 73.
    Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342–4349PubMedCrossRefGoogle Scholar
  74. 74.
    Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff JM, Robson M, Maki R, Brennan MF, Ladanyi M, DeMatteo RP, Besmer P (2003) Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9:3329–3337PubMedGoogle Scholar
  75. 75.
    Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708–710PubMedCrossRefGoogle Scholar
  76. 76.
    Dematteo R, Owzar K, Maki R et al (2007) Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III Trial ACOSOG Z9001. Proc Am Soc Clin Oncol Abstract No 10079Google Scholar
  77. 77.
    Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134PubMedCrossRefGoogle Scholar
  78. 78.
    DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR (2007) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245:347–352PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations